Wei Wang
Molecular Biology · Cancer Research · 2007–2008
A researcher in the Science corpus: 3 papers; trusts 1 researcher and is trusted by 0 researchers here, as inferred from the citation graph.
Subfields
- Molecular Biology — 28 citations into it
Whom Wei Wang trusts
Their strongest outbound trust, strongest first, inferred from their citations.
- K. Livak (in Molecular Biology)
Papers from Wei Wang's perspective
Ordered by how strongly the researchers Wei Wang trusts endorse each paper. Same corpus, a different order for every researcher.
- Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling (Nature)
- Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling (Hepatology)
- Anticancer drugs: To the rescue? (Nature reviews. Drug discovery)
- Cancer genes and the pathways they control (Nature Medicine)
- The Hallmarks of Cancer Review
- Real-time quantification of microRNAs by stem–loop RT–PCR (Nucleic Acids Research)
- Asymmetric and symmetric stem-cell divisions in development and cancer (Nature)
- An oligonucleotide microchip for genome-wide microRNA profiling in human and mouse tissues. (Proceedings of the National Academy of Sciences of the United States of America)
- c-Myc-regulated microRNAs modulate E2F1 expression (Nature)
- Biomarkers in Cancer Staging, Prognosis and Treatment Selection (Nature Reviews. Cancer)
Their papers
- MicroRNA-34b and MicroRNA-34c are targets of p53 and cooperate in control of cell proliferation and adhesion-independent growth. (2007) — 722 citations
- Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. (2008) — 647 citations
- EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma. (2008) — 732 citations